Supplementary Table 1 **In vitro susceptibility rates(%) of ESBL-producing E. coli and K. pneumoniae.**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Pathogens | *No.* | AMC | SAM | TZP | CAZ | FEP | ATM | AMK | GEN | IPM | MEM | CIP | LVX | SXT | CHL |
|  | | | | | | | | | | | | | | | |
| Total  *E.coli* | 641 | 59.2 | 27.6 | 86.5 | 56.4 | 31.0 | 45.1 | 98.6 | 57.0 | 93.7 | 95.1 | 40.8 | 41.1 | 51.1 | 71.3 |
| ESBL-producing  *E.coli* | 31 | 64.5 | 11.8 | 90.3 | 35.5 | 0.0 | 19.4 | 96.8 | 58.1 | 100 | 100 | 19.4 | 22.6 | 47.8 | 70.6 |
| ST 131  *E. coli* | 9 | 88.9 | 0.0 | 88.9 | 33.3 | 33.3 | 33.3 | 100 | 66.7 | 100 | 100 | 11.1 | 22.2 | 55.6 | 100 |
| Non-ST 131  *E. coli* | 22 | 54.6 | 16.7 | 90.9 | 36.4 | 9.1 | 13.6 | 91.7 | 54.6 | 100 | 100 | 22.7 | 22.7 | 36.4 | 66.7 |
|  | | | | | | | | | | | | | | | |
| Total  *K. pneumoniae* | 335 | 58.0 | 44.4 | 63.3 | 59.5 | 54.6 | 57.3 | 89.9 | 61.2 | 70.0 | 70.9 | 61.4 | 66.1 | 64.5 | 58.2 |
| ESBL-producing  *K. pneumoniae* | 28 | 14.3 | 0.0 | 50.0 | 14.3 | 7.1 | 17.9 | 85.7 | 25.0 | 85.7 | 89.3 | 18.5 | 46.4 | 19.2 | 25.0 |
| ST 11  *K. pneumoniae* | 5 | 0.0 | 0.0 | 20.0 | 20.0 | 20.0 | 0.0 | 33.3 | 20.0 | 40.0 | 40.0 | 0.0 | 0.0 | 60.0 | 0.0 |
| Non-ST 11  *K. pneumoniae* | 23 | 13.0 | 0.0 | 60.9 | 43.5 | 43.5 | 21.7 | 88.9 | 26.1 | 95.7 | 100 | 18.2 | 56.5 | 8.7 | 11.1 |
| Total (ESBL-producers) | 59 | 40.7 | 6.1 | 71.2 | 25.4 | 3.4 | 18.6 | 91.5 | 42.4 | 93.2 | 94.9 | 19.0 | 33.9 | 32.7 | 48.5 |
| Total  (*E.coli+K.pneumoniae*) | 976 | 58.4 | 37.0 | 72.2 | 58.3 | 45.5 | 52.6 | 93.2 | 59.6 | 79.1 | 80.2 | 53.5 | 56.5 | 58.9 | 64.0 |

*AMC: amoxicillin/clavulanate; SAM: ampicillin/sulbactam; TZP: piperacillin/tazobactam; CAZ: ceftazidime; FEP: cefepime; ATM: aztreonam; AMK: amikacin; GEN: gentamicin; IPM: imipenem; MEM: meropenem; CIP: ciprofloxacin; LVX: levofloxacin; SXT: andtrimethoprim-sulfamethoxazole; CHL: chloramphenicol.*